Categories

The next industrial revolution will be biological. By turning cells into factories, synthetic biology changes how we make everything from plastic to food to medicine. But achieving those goals will require overcoming the limitations of DNA design. This is still…

Monoclonal antibodies represent an important class of therapies for an ever-increasing number of diseases, infections, and health conditions. That’s why scientists around the world are working to improve the processes required to engineer new antibody candidates for therapeutic use. The…

Since the start of the COVID-19 pandemic, the Codex DNA team has been working hard to ensure that our customers have access to the tools they need to help in the fight against this public health scourge. We currently offer…

At a recent Oxford Global NextGen Omics UK congress, our own Kirsty Maclean gave a presentation about how the BioXp™ system is powering advances in cell engineering. While she started with a high-level view of how synthetic biology applies to…

One of the most popular applications of synthetic biology is to confer desired traits to an organism. Designing a range of possibilities and then testing each one for fitness, productivity, stability, or some other goal is critically important as the…

Back in 2013, I played a small role in response to what then seemed like the next potential pandemic — an outbreak of H7N9, an avian influenza virus. At the time, I was working with Novartis scientists, and we were…

If you were there for the early days of synthetic biology, you probably remember it the way we do: a relatively small number of academic scientists toiling in labs to build key parts, like toggle switches, and tinkering with the…

In the age of COVID-19, there has been a ton of scientific interest in nanobodies, or single-domain antibodies that can be used for finely targeted viral vaccines. It’s also been a hot topic among users of our BioXp™ system —…

Breast cancer is now recognized as the most common malignancy worldwide among women, irrespective of age. Today’s standard of care and breast cancer management relies heavily on chemotherapy, hormone therapy, and targeted therapy. However, there is still much to be…

The Codex DNA team really enjoyed attending this year’s virtual Global Synthetic Biology Conference hosted by SynBioBeta. If you missed the event, we’ve got you covered — here’s our take on highlights from the meeting. BioXp™ system in the spotlight…

For cancer patients with few other treatment options, the need for new targeted immunotherapies is genuinely a matter of life or death. So how to accelerate the development of new therapies? One key component is automated DNA synthesis. That was…

For BioXp™ system users, antibody drug discovery is one of the most popular applications. That’s why we were delighted to participate in the recent Oxford Global Biologics virtual conference, with a presentation from our own Kirsty Maclean, Director of Applications…

Several recent publications from the rockstar team at GigaGen illustrate how they are using the BioXp™ system to streamline antibody drug discovery workflows. It’s tough to overstate the importance of this area of research: monoclonal antibodies, antibody drug conjugates, and…